151 related articles for article (PubMed ID: 35466065)
1. The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection.
Xiong KG; Ke KY; Chen LF; Kong JF; Lin TS; Lin QB; Lin S; Zhu YY
Hepatobiliary Pancreat Dis Int; 2023 Aug; 22(4):366-372. PubMed ID: 35466065
[TBL] [Abstract][Full Text] [Related]
2. Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma.
Xiong KG; Ke KY; Kong JF; Lin TS; Lin QB; Lin S; Zhu YY
World J Surg Oncol; 2024 May; 22(1):117. PubMed ID: 38698475
[TBL] [Abstract][Full Text] [Related]
3. Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma.
Xiong KG; Lin TS; Kong JF; Lin QB; Chen LF; Ke KY
Medicine (Baltimore); 2023 Mar; 102(9):e33062. PubMed ID: 36862923
[TBL] [Abstract][Full Text] [Related]
4. Sex Differences in the Impact of Metabolic Dysfunction-associated Fatty Liver Disease on the of Patients with Hepatocellular Carcinoma After Radical Resection.
Huang J; Wei S; Tang Y; Zhang Q; Luo H; Tang Z; Tang Y; Liu H; Huang W; Dong X; Yang J
J Cancer; 2023; 14(7):1107-1116. PubMed ID: 37215444
[No Abstract] [Full Text] [Related]
5. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
[TBL] [Abstract][Full Text] [Related]
6. Sarcopenia Imperils Postoperative Long-Term Survival in HCC Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Propensity Score Matching Analysis.
Kong Q; Yi M; Teng F; Li H; Chen Z
J Hepatocell Carcinoma; 2023; 10():1367-1377. PubMed ID: 37605756
[TBL] [Abstract][Full Text] [Related]
7. The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.
Shimose S; Hiraoka A; Casadei-Gardini A; Tsutsumi T; Nakano D; Iwamoto H; Tada F; Rimini M; Tanaka M; Torimura T; Suga H; Ohama H; Burgio V; Niizeki T; Moriyama E; Suzuki H; Shirono T; Noda Y; Kamachi N; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
Hepatol Res; 2023 Feb; 53(2):104-115. PubMed ID: 36149726
[TBL] [Abstract][Full Text] [Related]
8. Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.
Xue J; Wang QX; Xiao HM; Shi MJ; Xie YB; Li S; Lin M; Chi XL
Cancer Manag Res; 2022; 14():2193-2202. PubMed ID: 35859711
[TBL] [Abstract][Full Text] [Related]
9. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection.
Lin YP; Lin SH; Wang CC; Lin CC; Chen DW; Chuang CH; Huang PY; Hung CH; Yang SY; Cho WR; Chen YS; Tsai MC
J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442328
[TBL] [Abstract][Full Text] [Related]
10. Effects of Clonorchis sinensis combined with Hepatitis B virus infection on the prognosis of patients with Hepatocellular Carcinoma following Hepatectomy.
Li YK; Zhao JF; Yang CL; Zhan GH; Zhang J; Qin SD; Zhou M; Li MJ; Huang JT; Kong FY; Huang H; Chen JH; Xiang BD
PLoS Negl Trop Dis; 2023 Jan; 17(1):e0011012. PubMed ID: 36638133
[TBL] [Abstract][Full Text] [Related]
11. Association of type 2 diabetes mellitus with incidences of microvascular invasion and survival outcomes in hepatitis B virus-related hepatocellular carcinoma after liver resection: A multicenter study.
Zhang XP; Chai ZT; Feng JK; Zhu HM; Zhang F; Hu YR; Zhong CQ; Chen ZH; Wang K; Shi J; Guo WX; Chen CS; Wu MC; Lau WY; Cheng SQ
Eur J Surg Oncol; 2022 Jan; 48(1):142-149. PubMed ID: 34452770
[TBL] [Abstract][Full Text] [Related]
12. [A new prognostic score system of hepatocellular carcinoma following hepatectomy].
Wang YK; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Li MX; Chen X; Wu XL; Mao R; Hu XH; Hu HJ; Liu JM; Cai JQ
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):903-909. PubMed ID: 29262506
[No Abstract] [Full Text] [Related]
13. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma.
Chen VL; Yeh ML; Yang JD; Leong J; Huang DQ; Toyoda H; Chen YL; Guy J; Maeda M; Tsai PC; Huang CF; Yasuda S; Le AK; Dang H; Giama NH; Ali HA; Zhang N; Wang X; Jun DW; Tseng CH; Hsu YC; Huang JF; Dai CY; Chuang WL; Zhu Q; Dan YY; Schwartz M; Roberts LR; Yu ML; Nguyen MH
Hepatol Commun; 2021 Jan; 5(1):122-132. PubMed ID: 33437906
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC.
Liu L; Xie S; Teng YX; Deng ZJ; Chen K; Liu HT; Huo RR; Liang XM; Guo PP; Yang DL; Ma L; Xiang BD; Li LQ; Zhong JH
Front Oncol; 2021; 11():783339. PubMed ID: 35127490
[TBL] [Abstract][Full Text] [Related]
15. Impact of perioperative allogeneic blood transfusion on the long-term prognosis of patients with different stage tumors after radical resection for hepatocellular carcinoma.
Peng T; Wang L; Cui H; Li X; Liu M; Yu J; Wu J; Zhao G; Liu Z
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):620-627. PubMed ID: 32988700
[TBL] [Abstract][Full Text] [Related]
16. Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC.
Yang T; Hu LY; Li ZL; Liu K; Wu H; Xing H; Lau WY; Pawlik TM; Zeng YY; Zhou YH; Gu WM; Wang H; Chen TH; Han J; Li C; Wang MD; Wu MC; Shen F
J Gastrointest Surg; 2020 Feb; 24(2):320-329. PubMed ID: 30617773
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy.
Chen W; Hu S; Liu Z; Sun Y; Wu J; Shen S; Peng Z
Hepatol Int; 2023 Apr; 17(2):406-416. PubMed ID: 36645648
[TBL] [Abstract][Full Text] [Related]
18. [Correlation between postoperative neutrophil to lymphocyte ratio and recurrence and prognosis of hepatocellular carcinoma after radical liver resection].
Wu XL; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Cai JQ
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):365-371. PubMed ID: 29860764
[No Abstract] [Full Text] [Related]
19. Association of Preoperative Hypercoagulability with Poor Prognosis in Hepatocellular Carcinoma Patients with Microvascular Invasion After Liver Resection: A Multicenter Study.
Zhang XP; Zhou TF; Wang ZH; Zhang F; Zhong CQ; Hu YR; Wang K; Chai ZT; Chen ZH; Wu MC; Lau WY; Cheng SQ
Ann Surg Oncol; 2019 Nov; 26(12):4117-4125. PubMed ID: 31321582
[TBL] [Abstract][Full Text] [Related]
20. Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma.
Xie X; Zheng M; Guo W; Zhou Y; Xiang Z; Li Y; Yang J
Sci Rep; 2022 Aug; 12(1):13969. PubMed ID: 35978032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
